VaxGen sells anthrax vaccine candidate to Emergent BioSolutions
http://www.forbes.com/afxnewslimited/feeds/afx/2008/05/05/afx4967820.html
SOUTH SAN FRANCISCO, CA (Thomson Financial) - Biopharmaceutical company VaxGen Inc. said it has completed the sale of all assets and rights related to its recombinant protective antigen (rPA) anthrax vaccine product candidate and related technology to Emergent BioSolutions Inc. Under the terms of the transaction, Emergent BioSolutions paid VaxGen an initial $2 million and may be obligated to pay up to an additional $8 million in milestone payments, plus specified percentages of future net sales.
SOUTH SAN FRANCISCO, CA (Thomson Financial) - Biopharmaceutical company VaxGen Inc. said it has completed the sale of all assets and rights related to its recombinant protective antigen (rPA) anthrax vaccine product candidate and related technology to Emergent BioSolutions Inc. Under the terms of the transaction, Emergent BioSolutions paid VaxGen an initial $2 million and may be obligated to pay up to an additional $8 million in milestone payments, plus specified percentages of future net sales.
